Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

ChroMet Elucidating the role of macroH2A1.2 histone variant as a metabolic sensor in the epigenetic regulation of leukaemia cell fate.

Coordinator
Fundacio Institut De Recerca Contra La Leucemia Josep Carreras, Spain
Runs
1 August 2024 to 31 July 2026
Status
Running
EU funding
€165k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101108823

What the project is doing

In the project's own words, from its summary on CORDIS.

The initiation and maintenance of leukaemia are often regulated through the interaction of epigenetic mechanisms and metabolism, but how these affect each other, is not always fully understood. One of the epigenetic mechanisms that alter cell fate is the replacement of replication-coupled histones with non-canonical variants. MacroH2A (mH2A) variants (mH2A1.1, mH2A1.2 and mH2A2) have a large, metabolite-binding macrodomain and differ from each other solely in the structure of their ligand-binding pocket.

Of those three, only mH2A1.1 has known ligands, while the binding partner and corresponding biological functions of mH2A1.2, are still unknown. The preliminary data suggest phospholipid molecules as unique ligands of mH2A1.2. At the same time, they show that the MACROH2A1 is required for the maintenance of the stemness of leukaemia stem cells and leukaemia itself. During the ChroMet project, by using cutting-edge techniques in cell and molecular biology, computational biology and biochemistry, I aim i) to confirm the identity of putative ligands of mH2A1.2 and to biophysically characterize the binding interaction, and ii) to test the contribution of the newly identified metabolite-binding capacity of mH2A1.2 on the leukemia cell differentiation and tumorigenicity.

The findings of the project will allow me to describe the mH2A1.2 as an entirely novel metabolic sensor on chromatin, which, through the binding of phospholipid ligands, regulates cell metabolism and impacts leukaemia cell fate. The complementary knowledge and expertise of the hosting group (in epigenetics and metabolism), the hosting institute and long-standing collaborators (in leukemia research), and my own (in biochemical analyses of protein-ligand interactions) will ensure the successful realization of the proposed project and contribute to the development of my career as an independent researcher, committed to exploring an interplay between epigenetics, metabolism and cancer.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Recerca Contra La Leucemia Josep CarrerasBadalonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI